VIGORSerious CV thrombotic eventsThree Different Endpoints

64

45

35

32

19

18

0

20

40

60

80

Investigator

Adjudicated

APTC 1

# patients with events

rofecoxib

naproxen

APTC 1: Anti-platelet Trialists’ Collaboration composite

Previous slide

Next slide

Back to first slide

View graphic version